---
document_datetime: 2025-11-18 11:05:22
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vizamyl-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vizamyl-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.5170471
conversion_datetime: 2025-12-20 00:52:39.466522
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## VIZAMYL

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA / | This was an application for a group of | 18/11/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000312794   | variations.   | PL   |
|---------------------|---------------|------|

<div style=\"page-break-after: always\"></div>

|                                         | packaging site, manufacturer responsible for batchrelease,site wherebatch control takes place,or supplier of a startingmaterial, reagent orexcipient(when mentioned in the dossier)*-Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.a Tightening of specification limits - Accepted   |            |                            |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------|
| Variation typeIA_IN / EMA/VR/0000296322 | Thiswas anapplicationfor agroupof variations. A.5Change inthename and/oraddress of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.aThe activities for which the manufacturer/importer is responsibleincludebatchrelease-Accepted A.ADMINISTRATIVECHANGES-A.4Change in the name and/or address of:a manufacturer(includingwhererelevant                                                                                                                                                                                                                                          | 22/09/2025 | Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                          | quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier)- Accepted   |                                                                                                                                                                                                                                             |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR/EMA/PSUR/0000248481 |                                                                                                                                                                                                                                                                                                                                                                                                     | Basedon thePRACreviewofdataonsafety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing flutemetamol(18f)remainsunchangedand thereforerecommendsthemaintenanceofthe marketing authorisation(s). |